All In Biotech

Drug Trial Radar · NCT04835805

A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.

A Phase Ib, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-Mutant Advanced Melanoma Who Have Received Anti-PD-1/PD-L1 Therapy

Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

65

Actual

Start

May 13, 2021

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Genentech, Inc.Roche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Apr 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, pharmacokinetics, and activity of belvarafenib as a single agent and in combination with either cobimetinib or cobimetinib plus nivolumab in patients with NRAS-mutant advanced melanoma who have received anti-PD-1/PD-L1 therapy.

Conditions

  • Melanoma

Interventions

  • BelvarafenibDrug

    Twice daily (BID), continuous dosing

  • CobimetinibDrug

    Once daily (QD) or three times weekly (TIW) for 21 days, 7 days off

  • NivolumabDrug

    Once every 4 weeks (Q4W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Dose Limiting Toxicity (DLTs)Time frame: 28 Days from Cycle 1, Day 1
  2. Percentage of Participants With Adverse EventsTime frame: From Cycle 1, Day 1 Up to 4 Years

Locations

20 sites in 5 countries. Site status is shown where the registry gives one.

  • California Pacific Medical Center Research Institute

    San Francisco, California

  • UCSF Helen Diller Family CCC

    San Francisco, California

  • University of Colorado Cancer Center

    Aurora, Colorado

  • University of Iowa

    Iowa City, Iowa

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland

  • Washington University School of Medicine

    St Louis, Missouri

  • Memorial Sloan Kettering

    New York, New York

  • Sarah Cannon Research Institute / Tennessee Oncology

    Nashville, Tennessee

  • Calvary Mater Newcastle

    Waratah, New South Wales, Australia

  • Peter MacCallum Cancer Centre-East Melbourne

    Melbourne, Victoria, Australia

  • Linear Clinical Research Ltd

    Nedlands, Western Australia, Australia

  • Ottawa Hospital Regional Cancer Centre

    Ottawa, Ontario, Canada

  • Princess Margaret Hospital

    Toronto, Ontario, Canada

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • Klinikum Mannheim GmbH Universitätsklinikum

    Mannheim, Germany

  • Universitatsklinikum Tubingen

    Tübingen, Germany

  • Universitätsklinikum Würzburg

    Würzburg, Germany

  • Asan Medical Center - PPDS

    Seoul, South Korea

  • Samsung Medical Center - PPDS

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.